Droxidopa Capsule
Product Images NDC 0904-7394

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Droxidopa (NDC 0904-7394). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Droxidop-capsules100-mg-90s-label (Droxidop Capsules100 mg 90s Label)

Droxidopa 100 mg capsules label manufactured by MAJOR Pharmaceuticals. The label states each capsule contains 100 mg of droxidopa and comes in a bottle of 90 capsules. Storage instructions, warnings to keep out of reach of children, and manufacturer details (MSN Pharmaceuticals Inc., Piscataway, NJ) are included. The label features barcodes and NDC 0904-7392-89.*

FDA Label Image

Droxidop-capsules200-mg-90s-label (Droxidop Capsules200 mg 90s Label)

Droxidopa Capsules 200 mg oral dosage form label by Major Pharmaceuticals. The label indicates 90 capsules per container with the NDC 0904-7393-89. It includes storage instructions, a barcode, and manufacturer information for MSN Pharmaceuticals Inc. It is marked Rx Only.*

FDA Label Image

Droxidop-capsules300-mg-90s-label (Droxidop Capsules300 mg 90s Label)

Droxidopa Capsules 300 mg label from Major Pharmaceuticals showing a 90-capsule container. The label includes storage instructions, manufacturer and distributor information, dosage reminder, and warnings. The label features the NDC number 0904-7394-89 and indicates the product is prescription only.*

FDA Label Image

Figure-2 (Droxidopa Figre 02)

A bar chart comparing the percentage of subjects reporting improvement in OHSA Question 1, with improvement scores from -8 (worse) to 8 (better) on the x-axis, and percent of subjects on the y-axis. The chart shows separate data for placebo (white bars) and Droxidopa (black bars) groups.*

FDA Label Image

Figure-01 (Droxidopa Figure 01)

A line graph showing the mean change in dizziness over 8 weeks during a double-blind treatment phase comparing Droxidopa and placebo groups. The y-axis measures mean change in dizziness, and the x-axis shows weeks from baseline to week 8. The Droxidopa group demonstrates a greater and sustained reduction in dizziness compared to placebo, with notable difference at week 1 (p < 0.05). Error bars indicate variability around measurements.*

FDA Label Image

Structure (Droxidopa Structure)

Chemical structure of Droxidopa showing its molecular arrangement including a benzene ring with two hydroxyl groups, and functional groups including hydroxyl, amino, and carboxyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.